Michelle Xia, Ph.D.
Founder, Chairwoman, President and CEO
Dr. Michelle XIA, the key founder of Akeso, Inc., has been the chairwoman, president and CEO of the Company since its inception on March 19, 2012. In these roles, Dr. XIA has been mainly responsible for the overall strategic and operational management of the Company.
Dr. XIA has over 27 years of experience in the pharmaceutical industry and academic research. Prior to founding our Group, Dr. XIA held senior leadership roles at Crown Bioscience Inc., where she played a decisive role in constructing Crown Bioscience’s platform, building its team, setting and implementing its strategies, and forging its joint venture with Pfizer (the Pfizer-Crown Asian Cancer Research Centre). From July 2006 to March 2008, Dr. XIA served as a senior scientist and group leader at PDL BioPharma, Inc. (later acquired by AbbVie). From January 2006 to June 2006, Dr. XIA served as a senior process development scientist at Bayer Corporation in the U.S.. At both PDL BioPharma and Bayer, Dr. Xia oversaw CMC, process development and manufacturing of therapeutic protein and antibody drugs. Dr. XIA began her pharmaceutical career at Axys Pharmaceuticals, Inc. (later acquired by Celera Genomics), where she held both scientific and managerial roles in drug discovery programs from December 2000 to December 2005, overseeing a broad range of activities from target validation through IND-enabling studies.
Dr. XIA received her bachelor’s degree in biochemistry from Sun Yat-sen University in the PRC in 1988. She earned her Ph.D. degree in molecular biology and microbiology from Newcastle University in the U.K. in 1994. Dr. XIA completed her postdoctoral research training at the University of Glasgow in the U.K. from 1993 to 1996, and she also conducted the cancer immune therapy research at the University of Louisville School of Medicine in the U.S. from 1996 to 2000.
Over the years, Dr. XIA has served important roles in numerous influential organizations, including a member of the Special Committee for Monoclonal Antibody of the China Medicinal Biotech Association, a committee member of the Special Committee for Science and Technology Innovation of China Overseas Returnee Entrepreneur Investment Association, an advisory committee member of the Chinese Antibody Society, and a director of Tongxieyi Antibody Talent Club. Dr. XIA has also received numerous awards and recognitions for her contributions to both the pharmaceutical industry and commercial enterprises. Dr. XIA has been selected into “Major National Talent Programs” for the “Recruitment Program of Global Experts” of the Organization Department, and the “Innovative Talent Promotion Program” administered by the Ministry of Science and Technology. In July 2015, Dr. XIA and her team were awarded the “Top Chinese Overseas Returnee Star-up Company” by the Overseas Chinese Affairs Office of the State Council, and Dr. XIA was also recognized for her role as the team leader of selected innovation and entrepreneurial team winners of the “Pearl River Talents Scheme” of Guangdong Province in April 2018. In June 2018, Dr. XIA received “The Seventh National Overseas Returnee Contributions Award” . In 2020, Dr. XIA was selected into Forbes’ Powerful Women in Technology 2020.